Encyclopedia of contested claims
Research on vitamin D supplementation and all-cause mortality is mixed. Large trials in generally healthy adults often find little or no overall mortality difference, while some reviews suggest possible benefit in selected groups or with particular dosing patterns.
8 reviewing models concluded the claim is mixed by the available evidence.
The Adjudged panel has not yet completed its review of this claim. This draft summarizes the main issues likely to matter for adjudication, including trial populations, baseline vitamin D status, dose and dosing schedule, length of follow-up, and whether mortality was a primary or secondary outcome.
Research on vitamin D supplementation and all-cause mortality is mixed. Large trials in generally healthy adults often find little or no overall mortality difference, while some reviews suggest possible benefit in selected groups or with particular dosing patterns.
The claim asks whether taking vitamin D supplements reduces death from any cause, often called all-cause mortality. This is broader than asking whether vitamin D improves blood vitamin D levels, bone markers, fall risk, fracture risk, cancer outcomes, cardiovascular outcomes, or immune outcomes. The key comparison is usually vitamin D supplementation versus placebo or no supplementation, followed over months or years.
The question matters because vitamin D is inexpensive, widely available, and commonly recommended for people with low vitamin D status or limited sun exposure. It is also relevant because many adults take vitamin D without a diagnosed deficiency, hoping for general health or longevity benefits.
A careful assessment needs to distinguish between different populations. People who are vitamin D deficient, older adults in institutions, people with limited sun exposure, and people with chronic illness may not have the same expected response as generally healthy community-dwelling adults. The dose, daily versus intermittent schedule, use of calcium, and baseline nutritional status may also affect results.
Randomized trials and meta-analyses generally suggest that vitamin D supplementation reliably raises vitamin D blood levels, but the link to lower all-cause mortality is less consistent. Some pooled analyses have reported small mortality differences favoring vitamin D, especially for vitamin D3, while others find little effect once large modern trials are included.
Large primary-prevention trials in broadly healthy adults, such as VITAL and D-Health, did not report a clear overall reduction in all-cause mortality from vitamin D supplementation during the main follow-up period. These trials are important because they were large and randomized, but many participants were not severely deficient at baseline, which may limit their ability to detect benefits in deficient groups.
Earlier meta-analyses sometimes suggested mortality reductions in older populations or in studies using daily vitamin D3, but the size of the estimated effect was usually modest. Some analyses also raise concerns that results differ by study quality, co-supplementation with calcium, adherence, baseline deficiency, and how mortality outcomes were collected.
There is less support for the idea that large intermittent bolus doses reduce mortality. Some studies of monthly or annual high-dose vitamin D have not shown mortality benefit, and high bolus strategies have raised separate concerns in fall and fracture research.
The biggest uncertainty is whether specific subgroups benefit more than the general adult population. People with very low baseline vitamin D levels, older adults in residential care, people with malabsorption, and people with limited sunlight exposure may be more relevant groups than vitamin-D-replete adults in population-wide trials.
Another uncertainty is the best dose and schedule. Daily or weekly moderate-dose vitamin D3 may not have the same effects as very large monthly or annual doses, and vitamin D2 may not perform the same as vitamin D3 in all settings.
Mortality is also a difficult endpoint for nutrition trials. Many studies are not primarily designed to test mortality, follow-up may be too short, and small mortality effects require very large sample sizes to measure reliably.
The umbrella claim is actually several claims bundled into one. Each needs its own evaluation.
| Model | Part 1 | Part 2 | Part 3 | Overall |
|---|---|---|---|---|
| Grok 4.3 | Mixed · 58% | Unclear · 46% | No · 62% | Mixed · 70% |
| Mistral Medium 3.5 | Mixed · 58% | Unclear · 46% | No · 62% | Mixed · 70% |
| Llama 4 Maverick | Mixed · 58% | Unclear · 46% | No · 62% | Mixed · 70% |
| DeepSeek V4 Pro | Mixed · 58% | Unclear · 46% | No · 62% | Mixed · 70% |
| OpenAI GPT-5.4 | Mixed · 58% | Unclear · 46% | No · 62% | Mixed · 85% |
| Claude Opus 4.7 | Mixed · 58% | Unclear · 46% | No · 62% | Mixed · 45% |
| Gemini 3.1 Pro | — | — | — | Incomplete |
| Qwen 3.7 Max | Mixed · 58% | Unclear · 46% | No · 62% | Mixed · 85% |
| Kimi K2.6 | — | — | — | Incomplete |
| GLM 5.1 | Mixed · 58% | Unclear · 46% | No · 62% | Mixed · 85% |
The current evidence leans one way. But we're not committed to the conclusion, we're committed to the evidence.
Vitamin D supplementation does not produce a consistent or clinically meaningful reduction in all-cause mortality. Large placebo-controlled trials in generally healthy adults (VITAL, D-Health) report hazard rat...
The evidence does not support a broad claim that vitamin D supplementation reduces all-cause mortality in generally healthy adults. Large randomized controlled trials (RCTs), such as the VITAL study (NEJM, 2018...
The claim that vitamin D supplementation reduces all-cause mortality is uncertain and depends on the population and dosing regimen. Confidence in the assessment is moderate due to mixed evidence from various st...
The claim that vitamin D supplementation reduces all-cause mortality is not supported by consistent high-certainty evidence. Confidence in this overall conclusion is moderate. Key evidence: The largest individu...
Probably not overall. Best independent judgment: the broad claim “vitamin D supplementation reduces all-cause mortality” is not well supported for the general adult population. Evidence from large modern random...
Vitamin D supplementation does not produce a clear, reliable reduction in all-cause mortality in the general adult population, though the evidence is mixed and a small benefit in specific subgroups cannot be ruled out. Confidence: Moderate-to-high that the overall effect in generally healthy adults is null or very small; lower confidence about subgroup effects. Key evidence: - VITAL (NEJM, Manson et al. 2019): 2000 IU/day cholecalciferol in ~25,000 generally healthy US adults showed no significant reduction in all-...
Incomplete response: output limit reached before the answer finished.
Vitamin D supplementation does not significantly reduce all-cause mortality in the general, healthy adult population, though it may offer a mortality benefit for individuals with baseline vitamin D deficiency....
Incomplete response: output limit reached before a parseable answer.
Vitamin D supplementation does not reduce all-cause mortality in generally healthy adults, though it may provide a modest benefit in individuals with low baseline vitamin D status or high deficiency risk. Large...
